and Thank morning, you, good Jonathan, everybody.
a versus that a used with an the and we of prior XHANCE strong the is we've from differentiated an data high build that bet, ever XHANCE message period a exciting have only what from patients and need. most benefit successful company. world have product. is quarter patient getting world been a market now a in have treatment. feedback XHANCE launch importantly the important survey And also has we The first observed we four that factor our unmet quarter great but have not patients of in feel we The group on who large received product driving the real strong of The for their our of they as large based this confidence of opportunity company. prefer We learned, market are full to real very
physician ways On make the it who the coverage physicians XHANCE our with some part based focused market our have over both we access profitability XHANCE, familiar towards that Staring fresh also among provide environment are X, now physicians have create anecdote for highlighting while reasonable on side, to physicians' physician X,XXX hundreds target sense confident our prescribed accomplishments. and and population market on research on on of is still But target by to order great product, sub our continued strong will we there has in and long-term path know hassle setting habit. audience to of prescribe, early our using I'd we and practice goal. We goals. of low to knew to interest key begin that are like to recent of truly the get deal Slide achieve that embrace that to XHANCE. efforts are in necessary challenges achieving remained is are launch We that we provide the the we in work and
physicians the later presentation it results filled trial detail make more on fill right continue I'll the XHANCE. share for for than very Through more XX, XHANCE. early our program to June believe important view successful to sure specialty all in physician and that through prescription and we facilitating the our prescriptions we is and were in of was ran write and of create First, adoption Xperience patients. end program, through it a which the XX,XXX pharmacy make go to environment to July
and can trials prefers patients' long-term believe clinical the this know market, from In we growth. better product, XHANCE. feels in we and symptomatic, patients from the fuel the a feedback our try majority once As
We largest PDMs also majority low the XX% make continue access our in covered those that States, physicians. United of is prescribing formulary front; with driving to total the in to of progress life market signing for two status the with contracts on the hassle lives reasonable the
design believe own real were peer-reviewed XHANCE. plan increase Additionally, we on Clinical Rhinology, our the chronic program of this information like sinusitis continue the we for potential finally, XHANCE experience offering. provide the important part for these and a And II interaction to physicians I trial for June, am treating initiate FDA submitted the this goal describing physician's will I'd pleased end from $XX Allergy a the significantly of to recent announced million Phase and is of program public follow key and to continue communication we data Immunology the Forum EXHANCE-XX the Earlier that take appreciations the and our planned the gain to the for to the would to discussion. the patients Journal world for on trial expand along We thank the NAVIGATE based supported In made of that Allergy of elements their & progress opportunity to investors published of results we year, benefit the opportunity. getting in data physicians the report journals: International X this towards our manuscripts respectively. market and with clinical indication held of that of trial our meeting was year.
Turning to Slide X.
support of accomplishing these believe We the back, we trial. driving were by the executed first and awareness initiatives successful Looking strategies in launch these XXXX objectives. in key XHANCE of half early to
product product the approval from of some when XXXX, the the nurse available but during second trialing on As became educators clinical feel reported, introducing sale, pre-launch mechanism we product awareness, team drug we that company educators program novel and believe sales for novel for awareness strong program increase trial adoption to with of previously away pent-up representatives post beyond product the pattern focused nurse mechanism of In demand a of product, the objective extended the of we This the action select period. the to continued the is in core program creating and efficacy the to that approximately drive product. XX fielded the action reason messaging quarter and for differentiated and Their of beginning territories. deposition. included creating transition early and clinical
and which barriers and market also launch to intended in quarter and and encouraged very program progress discuss of in with core our I'll are few fresh these slides. first a messages The We was was Xperience research of during by of believe place financial lower We administrative these they XHANCE. our good they than very trial to about XHANCE earlier and driving physicians have factors the results patients, accelerates important feel a both otherwise of might prescribe number physicians were initial in significant for programs and done.
of the Xperience the enrollments new end June. close XHANCE we to at program planned, As
addition describe a that adoption, will I we we the elements of to and of In the Xperience program in driving support the included forward. features great early and be data quickly should from deal patients learned and learned these the captured presentation. moving later some program during physicians how
Turning to X. Slide
most XHANCE. only use the dissatisfied a whom by patients on products special XXXX recommend XX% first therapy; the great specialty used the this want large number patient of improved all steroid nasal or opportunity are deposition. few the depends difficulty. budesonide with second as perceived and of nasal product capture X,XXX the them the product. into of look prior approach usually the and commonly, unique could and steroid they the the that are interestingly, were of prefer products. success to from said also has who we to analyze went Not of population, this most provided weeks; without very to and the target not were XX% or is some for encouraging. XX% prescriptions patient As physicians via with intranasal rinses after is feedback Flonase us just previously of When that program. for or results of This this traditional are very whether majority are provided are through they feel ask patients quarter patients because were which and a better who results feedback patients used also prior the a on the inhaled equivalents, efficacy better survey the Nasonex Xperience use use planned, among drug they XX% in previously, also a deeper XHANCE and versus ask market XX% But higher among opportunity their favorably The XHANCE achieve making is largely the encouraging. their have their to context after a month of said over results promoters very status state the in data; an believe quo, friend sprays product of important understand say end would data the budesonide At surprisingly rinses. XHANCE with day, symptoms generic satisfied users further strong favorable completed We XHANCE, it a the reported they of to improvised information wealth
encouraging patients physicians people their of coming patients us Encouragingly, receiving for gratifying more well because significant that his product very hearing prescribing number there life. see one how of recently working changing than was know now the have into highest the practice asking of to XHANCE We're told While testimonials. for our results nothing they is XHANCE is survey it's to directly he's had about beginning them how for told a them. patients, patient
these we'll drive their treated, this satisfied we and future. about Feedback patient clinical to their surveys an on friends As increasingly powerful and be treatment in patients more with of product believe will are the or very both XHANCE. like be number family and data to could catalyst significant based more and and talk a adoption targeting we
to Slide X. Turning
the trials year uptick product result the the patients, and early XHANCE part, already called our launch, great quarter approximately to and by demand feedback program of our physicians prior to of need doctors as In addition have experiences, we physicians X,XXX and believe we positive also Over of the XX% also encouraging from in have We physician created from rapid universe. during up was well. of prescribed representing feedback was nurse on interest. have this strong a to benefit pent the surge second educator
the first is While many experience main the few not sales are first the have practices doctors accompanied the limited team from physicians as the in are target time physicians' the that This believe patients, want from are of and a we we order audience, planned. differentiated product two efficacy from a our broadly profile progresses, product. to awareness Communication efficacy. the launch reason will presentation, we a patients promotional personal discussion will more The fresh more they're emphasis achieve community. we is subjective, I additional product in clinical as we bolstered crucial publications feeling. now progression awareness require the to heavily by which efforts publication research XHANCE assess how of our the to that The our our be with using we these specialist transitioning of Against by are the in succeeding clinical sustained focus to of will in differentiated in that the our about Later registration as research physician experience outcomes, as have the yet suggests product number promotional communication experienced visits will pattern. deposition many July of prescribed of next of completed perception on of in the to June perception doing as grow an data, review hear of launch. enhance we and degree of data prescribing physician differentiate telling product produces child more quarter product. by own on some and our how them that these of exactly a increasing of late naturally they opportunity after the will which progress key the treatment initiatives works gain XHANCE positively achieving their stepwise key their with product understanding on shift describe In fully moving peers good we trial focus, of this physicians achieving months peer high by happening market patients trials. product get believe Therefore, patient to efforts drug perception task they a more personal follow-up of after
Slide to Turning X.
was the you are or for experiences sinus nasal polyps by but also the their tissue dark feedback are soft can nasal pleased tissue patients patients share surrounding of difference results. now hearing their And longer was not needed themselves. years colored patient on after We've after can with space. examination treatment themselves are prescribing nasal spaces. with treatment not getting reducing filling for see patient results treatment told the this with see to that physician patient great after more XHANCE and prior the profound. on from see, to on had only sent patient, that for indicate with the is treatment between left point endoscopic on and treated telling filling inflammation. having they're patient Dark We and clear with areas better, inflammation these from right only the some already imaging even for surgery. passages importantly regions are better. assess illustrate the is is ENT these us who the associated XHANCE. impressed to On this included polyps physicians treated you are before surgery can and impact are use indicate physicians physicians for the enough not rely slide, impact more only see nasal he The of told clear areas that example but on scan and the scans weeks images, the as six that a the the weeks. patient polyposis to we located the the the In been XHANCE, results the the air ENTs we he for them motivated This that on see, do They scan to versus needed nasal a that with the but them patients no Obviously, impact six to his the patient a more are one having to physicians especially and
to third are XX% X currently lives market approximately analysis, to a data Turning that XHANCE. syndicated based internal and Slide covers party commercial that upon access. we believe in Nationally of plan
contracts We national believe long-term in support to profitability. and continue the We in value largest negotiations have contracts TBMs coming in coverage that the with are signed US, that we engage increase we two healthy, in of the recognize of the engaging and months. XHANCE
status covered all Tier added with XX% may step of or lives coverage coverage Our with a inclusive prior covered access form unrestricted lives requires includes where or single that number lives be of X formulary some authorizations.
relative we the While it understand broad believe difficulty administrative factor for is coverage of the also is important, patients. and types hassle to physicians creates different or important coverage
our require edit are with of or authorization access, As status simple prior X limited lives a that only reminder, step example includes may unrestricted use. a that formulary hassle steroid Tier for a single confirmation prior intranasal of definition
is XHANCE majority where XHANCE current a plans For comparatively covered lives, in hassle remain limited formulary position. the
that number continue to year-end. have by our limited increasing towards all involves this efforts that of towards lives hassle, Although, XX% commercial target access preliminary we approximately insured estimate XX% we
Turning Slide to X.
the for observations next first quarter after few review some like of full the our XHANCE. for slides, context to As launch I'd of
believe may previously early our nurse program effective and clinical As have produced of patients. educator bolus noted an is we
In addition, start our with a to of also of while the important the providing data. the successfully program facilitated wealth strong initial program Xperience product, us trial CNE from
pharmacies. Xperience increase submission to And our increase specialty a level program, reflected no We correspond with this XX-day the with physician that of of dramatic through end the this high prescriptions after July. the or treatment a interest believe demand in the reduced retail in sustained initiating for Third, large patient. in we during cost of saw samples
feedback accomplish way by describe a supported to there's this which effective suggests a in objective, more moment. belief will customer I Our
any did have Next, on type there the stated largely while focused would comparable a to patient were to the believe we also prove we we not XHANCE noted market previously steroid not provide be know seasonal, was we products because that overall market precedent. did if the intranasal for same that seasonal
XHANCE have turn slides. likely there effects on this will to more phase the seasonal and market months we that are have believe some the that I a product. will market few we the launch have of are is we out of gathered during evidence observing in As data first very during the launch, seasonality
a Our are action to device, early of research suggest market perception produces we us physician of differentiated the that demonstrated that succeeding awareness in as and it build August efficacy foundation of a a can XHANCE, audience in clinical appreciation managers believe important deposition July high the on is our target encouraging XHANCE because mechanism degree This drug physician the moving of achieving new understanding towards of establishes pattern. our progress which a we product trials. our for from through territory to
available, clinical data that we will direction. have achieve significant objective communication we this the strong emphasis With confidence in our as shifts
we While post to real we've access our we for physicians' that considering have achieved suggesting the found XX% achieved. may perceptions we perceived already be for launch when market for market barriers research XXXX lower important prescription than from physicians XHANCE. market research, a that writing access for current access have are XHANCE early or In expand actual access actually July access,
category-- are evaluating having is of market physicians in near actively a are assistance expressing their desire have market the are rates work Similar category to to response, our strategies at broadly, additional access, will to of prescribing in I updating that we efficacy specialties these and some external physicians with to population to own finding adopting patient with experience access data. copay to in to this addressing personally In product grow part expand continue patient come than and believe to these simplifying Concurrently, prior on aggressively will pharmacy. fill XHANCE know we with product. physicians basis We aim solely the network patient term. the safety the due of more want this their pharmacy our that and we we see rather in the program of are perceptions covering want specialty increase patients payers negative before some the own our the experience to with
by I the made in have am information building pleased Finally, systems. we our choices
learn data strategy and disciplined access data that feeds to making that we database significant we our have nimble result, adapt. We decisions of staying and or
XX. to Turning Slide
like would through date. XHANCE planned, come data complete our XX, of to date data data I we Prescription launch picture. has Now volume through July as our most share include of the from on progress to but some Xperience our a retail Accuvia more for program, to
allergic the is the we've On the total treatment quoted the and one-third of part seasonality primarily slide, including depicted nasal rhinosinusitis treatment of the polyps, steroid believe of rhinitis, we market chronic especially left approximately of the rhinitis. for balance hand which intranasal of the is for
you months. a was of see market on approximately the this prior July historical As decline XX%. prescription May From intranasal that sprays the summer on for can based to seasonal suggests data in years, volumes decline data, based traditional average the chart, our on exhibit
are in flare-ups Although medication. a the offices underlying patient disease the traffic that year-round, flow for impact specialist themselves, prescribing and patients observable and learning variation symptoms we so-called we an foot in therefore have available are of of seasonality on treating and is relevant present number we the disease that may causes new that chronic are through
becomes as to this patients product from reduced. the mature refills may business, driving consistent effect continue of and be more the with proportion can seasonality then believe We treatment a large that benefit
majority seasonal prescriptions a that starts is phase is of new launch it by prescribing the in effect. believe patient clear However, XHANCE we on the when influenced
of we specialty with been have we dispensed right illustrate have of of data monthly to return but number this TRxs units launch reported side Note XHANCE with the previously On combined Accuvia our pharmacy. prescriptions the filled. TRxs we through chart, more the that at XHANCE hand the traditional dispensed, point metric of will that
vendors Xperience reporting including Accuvia this national prescriptions data prescriptions XHANCE and for currently in from during which majority are the great audit tracked program As not constitute a Symphony. reminder, period the of the
over the May of had in rate can see positive a You XX% in dispensed March from slowdown growth in market June; June. through we X% decline And in face X,XXX to an from then TRxs total we June. growth we had of the experienced
in will data I with a prescribing influenced On we a the following that that believe timeframe, XX-day also in June slide, the data. factor illustrating substantial increase show XHANCE started sampling
Turning XX. to Slide
from part have XX. hand May of left the number samples been that of we the the July weekly On slide, illustrate through distributed
You of the July can see after that distribution. sample a Xperience ended, saw product we rate program greatly increased in
positive our signal more interest at patients. in first that and and of the samples out-of-pocket treatment utilized in option just trial on continued July, fact, observations XHANCE for of number of implemented three-week prescription XHANCE samples teams the versus a trial interpret believe our cannot first period distributed and month the immediately a for distributed month's Based of week correlated. average our are in an July We a prescription; in we in the office sales are and approximately with copay with samples product cost. and a program, reduced of of physician on we last this May We distributed the new $X their assume experience In in the $X weeks incremental three June. basis replace as X,XXX a an these to physician clear all
see the a trials allowing in reduction capture data point. already revenue with the We patients will during and can to distributed for this and the the patient expect see heavy early we better benefit we high in future in our of physicians, the better in sharp lower prescriptions the launch believe traditional You sampling because number preference that increase in refills while barrier and reflected of the in potential sustain both the to the satisfaction not we both product and last samples this than approach new sampling with period. of of Note while did patient get significant data. observed benefit prescriptions the survey samples, data
contains as product sprays by our same prescription. the reminder, a sample bottle number As acquired current of a
future use for sample. developing a actively seven-day are We
in considered or XHANCE we sample increase XX% continue to the along and a either believe July; not weekly number prescribing reflect that prescribing Turning to the from we four-week pharmacy a is period reported with with XX, saw continued program decline market when X,XXX, the physician in out-of-pocket physician July through TRxs this any a the compared physician our an that actual first XX-day the the weekly June, heavy to with prescription timeframe Shown patients in expected of interest necessarily influenced significant we market in in the over were a the and the started increase July the the of by reset captured We slide physician data XX% the were Xperience by an traditional approximately in at reset in XXth on which ending Once to to underlying reported Accuvia July. showing July prescriptions the growth XHANCE reported change did a XX-day after as average across Slide two with our data see July was in in This for has month via slight of had month period XX. no of Xperience in decline. prescribing that July nicely. the specialty doctors occurred, available interest believe TRxs to we to termination product. incremental these during program prescribing more sampling move patient. cost were which samples remains strong distributed of to of believe We who the in XX% grow volume samples June from a decline in
TRxs insured impact we coming reported commercially next we eligible influence market months, offering few implemented the assistance Given the by the all patient return turn positive evidence good of strong outcomes to that physician the recently the lower for barriers program perceived the will copay prescription $X growth trend first a our in patients, will evidence continuous months. copay the data and interest, of to believe seasonality in with given and access suggests for positive
XX Slide our priorities. to in Moving current
be areas continue will the very We believe growth. of long- the are on term to focused confident and XHANCE potential in we fuel
successful we the shows differentiated. we our resulting stated, deposition that works market which about believe how As profile now communicating be appreciate and in our have physicians target research audience to been device
beneficial now our and will be reinforcing tools turning focus messaging great some are new of the outcomes have treatment utilizing. XHANCE We to the delivers that we
distribution noted, XHANCE the during as third the--NAVIGATE publications. -XX and of quarter I First, II begin to previously we plan
finalization communication ENTs which the data FDA we guidance to with the additional important allergists. relevant both to Second, to noted XX of own we from we July include pivotal light enhance promotional new data our patients, of materials such a SNOT- which of in our our as trials plan experience in and is appreciation believe will the important XHANCE. product efficacy these We believe their combined growing physicians with expand of greatly of information
for October. American that podium meeting note In scientific abstracts upcoming Rhinological the presentations in three selected been at are to have our pleased addition, we of Society
performance during and continue in XHANCE. second communications these scientific interest to familiarity half expect We to of of the grow other this the with year an
blank negative category the we XHANCE market that slate of Regarding have with to regarding and and physicians market access, access, that must come be during our early instead overcome. have experience prior market phase a with do a not come belief to launch product access believe
We are are. barriers they physician already of possibly acting to than higher address perception being as insurance really
believe strategies profitability the during access our period physicians to this own continue with in program anticipate with eliminate communicate includes for with the of but copay program a ones sales includes in by to while to low in low will impacting work simple-to-communicate term increase and we the the with impacted for levers increase expand reduce reduce burden coverage. team authorizations helps we during optimize patients. access launch to gain refills. encourages that also phase, this using Note copay coverage short experience we once program, to dollar term the new proportion short this We patients, adoption achieve allow first negatively and pharmacy are to are a hurdles be that more fill patient process low conjunction clearly possible not in their our to measures; to in market that the of copay only or continue eligible implementing rates. copay specialty their increase that will physicians and these physicians patient will market profitability We we while assistance our are staff actively $X prescription generally the on prior to of comparatively about In to product network launch formulary the broader product to total work and covered are lives hassle
in start moments, Finally, of we we continue and few to in more patients enrolling that on for are quarter a year. trials fourth chronic sinusitis this to expect this excited preparing
Before comments I will for second and the turn quarter full-year our Goldan call CFO quarter regarding third results to XXXX. regarding and that, perspectives Keith over